CYPH:NASDAQCypherpunk Technologies Inc. Analysis
Data as of 2026-03-28 - not real-time
$0.66
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Cypherpunk Technologies (CYPH) is trading at $0.6566, just below its 20‑day SMA of 0.6576 and well under the 50‑day (0.7106) and 200‑day (0.7014) averages, indicating short‑term weakness. The RSI sits at 46.9, signaling a neutral momentum without clear over‑bought or over‑sold conditions. A bullish MACD histogram (+0.0106) contrasts with a negative MACD line, suggesting a tentative upside reversal but not enough to outweigh the price‑below‑average trend. Volatility is extreme at roughly 143% over the past 30 days, and the computed beta of 1.9 points to amplified moves with the market. The stock’s PE ratio of 9.4 is markedly lower than the industry average of 16.0, while the price‑to‑book of 0.36 implies a deep discount to book value. However, the company reports zero revenue, negative operating cash flow of –$43.9M and a massive free‑cash‑flow deficit, underscoring a high cash‑burn environment.
Recent material news disclosed a $5 million investment into ZODL, a Zcash development lab, aligning CYPH with leading crypto investors and potentially expanding its digital‑asset portfolio. The balance sheet remains relatively clean with $14.0 million in cash and negligible debt, yet the max drawdown of ‑82.7% reflects historic price collapses. The dual focus on privacy‑enhancing crypto technologies and early‑stage biotech therapeutics adds layers of sector and regulatory uncertainty. Given the lack of earnings, the current valuation appears more “value‑oriented” than growth‑driven, but the speculative nature of its assets tilts the profile toward a blended outlook. Investors should weigh the attractive valuation multiples against the severe liquidity constraints and ongoing cash burn. In this context, a cautious stance is warranted, with short‑term patience and a view toward medium‑ to long‑term catalysts.
Recent material news disclosed a $5 million investment into ZODL, a Zcash development lab, aligning CYPH with leading crypto investors and potentially expanding its digital‑asset portfolio. The balance sheet remains relatively clean with $14.0 million in cash and negligible debt, yet the max drawdown of ‑82.7% reflects historic price collapses. The dual focus on privacy‑enhancing crypto technologies and early‑stage biotech therapeutics adds layers of sector and regulatory uncertainty. Given the lack of earnings, the current valuation appears more “value‑oriented” than growth‑driven, but the speculative nature of its assets tilts the profile toward a blended outlook. Investors should weigh the attractive valuation multiples against the severe liquidity constraints and ongoing cash burn. In this context, a cautious stance is warranted, with short‑term patience and a view toward medium‑ to long‑term catalysts.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- price below short‑term moving averages
- high volatility and beta
- ongoing cash burn with no revenue
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- $5M ZODL investment expanding crypto exposure
- valuation discounts relative to peers
- potential biotech trial milestones
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- long‑term appreciation of Zcash and privacy assets
- future commercialization of DKN‑01 and FL‑501
- deep book‑value discount offering upside if cash burn stabilizes
Key Metrics & Analysis
Financial Health
P/E Ratio9.4
ROE5.11%
ROA-21.61%
Debt/Equity0.03
P/B Ratio0.4
Op. Cash Flow$-43902000
Free Cash Flow$-174597632
Industry P/E16.0
Technical Analysis
TrendNeutral
RSI46.9
Support$0.50
Resistance$0.83
MA 20$0.66
MA 50$0.71
MA 200$0.70
MACDBullish
VolumeStable
Fear & Greed Index65.98
Valuation
GradeUndervalued
TypeBlend
Risk Assessment
Beta1.91
Volatility142.90%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.